Erythropoietin: a new perspective in cardiovascular therapy

https://doi.org/10.4081/monaldi.2008.414

Authors

  • Riccardo Raddino | riccardo.raddino@libero.it Sezione Malattie Cardiovascolari, Dipartimento Medicina Sperimentale Applicata, Università degli Studi di Brescia, Italy.
  • Debora Robba Sezione Malattie Cardiovascolari, Dipartimento Medicina Sperimentale Applicata, Università degli Studi di Brescia, Italy.
  • Giorgio Caretta Sezione Malattie Cardiovascolari, Dipartimento Medicina Sperimentale Applicata, Università degli Studi di Brescia, Italy.
  • Ivano Bonadei Sezione Malattie Cardiovascolari, Dipartimento Medicina Sperimentale Applicata, Università degli Studi di Brescia, Italy.
  • Melissa Teli Sezione Malattie Cardiovascolari, Dipartimento Medicina Sperimentale Applicata, Università degli Studi di Brescia, Italy.
  • Gregoriana Zanini Sezione Malattie Cardiovascolari, Dipartimento Medicina Sperimentale Applicata, Università degli Studi di Brescia, Italy.
  • Alberto Madureri Sezione Malattie Cardiovascolari, Dipartimento Medicina Sperimentale Applicata, Università degli Studi di Brescia, Italy.
  • Enrico Vizzardi Sezione Malattie Cardiovascolari, Dipartimento Medicina Sperimentale Applicata, Università degli Studi di Brescia, Italy.
  • Livio Dei Cas Sezione Malattie Cardiovascolari, Dipartimento Medicina Sperimentale Applicata, Università degli Studi di Brescia, Italy.

Abstract

Erythropoietin is a hormone produced by the kidney, which regulates proliferation, differentiation and maturation of red cells. Recombinant human EPO (rH-EPO) is well known to correct anaemia in patients with chronic renal failure in terminal stage. However, recent studies showed the existence of several not haematopoietic effects of erythropoietin. EPO receptors have been found to be expressed in several tissues, included the cardiovascular system. An increase in cardiac systolic function has been observed in patients with chronic heart failure treated with EPO. Other beneficial effects appear to be related to the pro-angiogenic properties on endothelial cells and could be useful for treatment of ischemic heart disease. These findings suggest that EPO could provide potential therapeutic benefits in the management of cardiovascular diseases beyond anaemia correction. This review focuses its attention on the pleiotropic effects of EPO and its future promising applications in cardiovascular pathology.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Downloads

Published
2016-01-26
Info
Issue
Section
Reviews
Keywords:
Erythropoietin, Apoptosis, Anemia, Ischemia, Myocardial infarction, Heart failure
Statistics
  • Abstract views: 495

  • PDF: 962
How to Cite
Raddino, Riccardo, Debora Robba, Giorgio Caretta, Ivano Bonadei, Melissa Teli, Gregoriana Zanini, Alberto Madureri, Enrico Vizzardi, and Livio Dei Cas. 2016. “Erythropoietin: A New Perspective in Cardiovascular Therapy”. Monaldi Archives for Chest Disease 70 (4). https://doi.org/10.4081/monaldi.2008.414.

Most read articles by the same author(s)

1 2 > >>